View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBioera 将来の成長Future 基準チェック /06現在、 Bioeraの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長8.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jul 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Negative equity (-€5.2m). Revenue has declined by 40% over the past year. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Revenue is less than US$1m (€449k revenue, or US$487k). Market cap is less than US$10m (€1.31m market cap, or US$1.42m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).New Risk • Nov 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$648k). Market cap is less than US$10m (€276.2k market cap, or US$295.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 301% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (301% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$661k). Market cap is less than US$10m (€1.33m market cap, or US$1.45m).Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.お知らせ • Aug 11Helon srl agreed to acquire Bioera S.p.A. (BIT:BIE).Helon srl agreed to acquire Bioera S.p.A. (BIT:BIE) on August 9, 2021.Is New 90 Day High Low • Mar 06New 90-day low: €0.23The company is down 13% from its price of €0.26 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €0.24The company is down 33% from its price of €0.36 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: €0.25The company is down 38% from its price of €0.40 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 2.0% over the same period.Is New 90 Day High Low • Oct 07New 90-day low: €0.29The company is down 36% from its price of €0.46 on 09 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 3.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bioera は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:B2A - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20231-620N/A3/31/20231-532N/A12/31/20221-444N/A9/30/20221-1144N/A6/30/20221-1833N/A3/31/20221-900N/A12/31/202110-2-2N/A9/30/202138-3-3N/A6/30/2021515-3-3N/A3/31/202186-3-3N/A12/31/202011-4-3-3N/A9/30/202014-4-2-2N/A6/30/202017-400N/A3/31/202022-500N/A12/31/201927-511N/A9/30/201931-511N/A6/30/201934-511N/A3/31/201937-501N/A12/31/201840-400N/A9/30/201841-4-1-1N/A6/30/201843-5-2-1N/A3/31/201845-5-2-1N/A12/31/201746-5-2-2N/A9/30/201747-4-3-2N/A6/30/201749-4-3-2N/A3/31/201751-3N/A-2N/A12/31/201653-3N/A-2N/A9/30/201655-3N/A-1N/A6/30/201657-3N/A0N/A3/31/201657-3N/A0N/A12/31/201557-3N/A-1N/A9/30/201556-3N/A-2N/A6/30/201555-3N/A-3N/A3/31/201554-3N/A-2N/A12/31/201452-2N/A0N/A9/30/201450-1N/A0N/A6/30/2014490N/A0N/A3/31/2014480N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: B2Aの予測収益成長が 貯蓄率 ( 1.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: B2Aの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: B2Aの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: B2Aの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: B2Aの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: B2Aの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/03/03 14:38終値2024/12/04 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioera S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jul 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (34% average weekly change). Negative equity (-€5.2m). Revenue has declined by 40% over the past year. Shareholders have been substantially diluted in the past year (70% increase in shares outstanding). Revenue is less than US$1m (€449k revenue, or US$487k). Market cap is less than US$10m (€1.31m market cap, or US$1.42m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
New Risk • Nov 07New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average daily change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (409% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$648k). Market cap is less than US$10m (€276.2k market cap, or US$295.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jul 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 301% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Negative equity (-€5.1m). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (301% increase in shares outstanding). Revenue is less than US$1m (€606k revenue, or US$661k). Market cap is less than US$10m (€1.33m market cap, or US$1.45m).
Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Fiorella Garnero is the most experienced director on the board, commencing their role in 2020. Independent Director Domenico Torchia was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 19Full year 2021 earnings releasedFull year 2021 results: Revenue: €19.8m (up 80% from FY 2020). Net income: €15.3m (up €18.9m from FY 2020). Profit margin: 77% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue.
お知らせ • Aug 11Helon srl agreed to acquire Bioera S.p.A. (BIT:BIE).Helon srl agreed to acquire Bioera S.p.A. (BIT:BIE) on August 9, 2021.
Is New 90 Day High Low • Mar 06New 90-day low: €0.23The company is down 13% from its price of €0.26 on 04 December 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €0.24The company is down 33% from its price of €0.36 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: €0.25The company is down 38% from its price of €0.40 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Oct 07New 90-day low: €0.29The company is down 36% from its price of €0.46 on 09 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 3.0% over the same period.